Cadrenal Therapeutics, Inc. Common Stock
CVKDNASDAQHealthcareBiotechnology
Previous close
$1.61
+$0.02 · +1.26%
CVKD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
19
Strong Down
Sentiment
41
Mixed
Risk resilience
22
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Quang X. Pham
- Listed since
- Jan 20, 2023
- Employees
- 5
Market position
Day range
Current $1.61
52-week range
Current $1.61
- Open
- $1.60
- Previous close
- $1.59
- Volume
- 36.25K
- 0.53× average
- Average volume
- 68.86K
- Average daily volume
- Market cap
- 5.74M USD
- Beta
- 1.86
- Market reference 1
- 50-day average
- $2.4852
- -35.22% below average
- 200-day average
- $6.0058
- -73.19% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 9.51M USD
- EV / EBITDA
- -0.72×
- Earnings yield
- -97.93%
- Free cash flow yield
- -93.22%
Profitability & efficiency
- Return on equity
- -483.34%
- Return on assets
- -305.95%
- Return on invested capital
- -491.51%
Financial health
- Current ratio
- 2.72×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | — | — | — | 1.27K USD |
| Gross profit | — | — | — | −1.27K USD |
| Research and development | 4.1M USD | 4.21M USD | 4.08M USD | 392.86K USD |
| Selling, general, and administrative | 9.35M USD | 6.75M USD | 3.55M USD | 2.31M USD |
| Operating expenses | 13.46M USD | 10.96M USD | 7.63M USD | 2.7M USD |
| Interest income | 223.82K USD | 309.25K USD | 249.09K USD | — |
| Interest expense | — | — | 17.1K USD | 107.11K USD |
| Depreciation and amortization | 6.87K USD | 1.88K USD | 1.98K USD | 1.27K USD |
| Operating income | −13.46M USD | −10.96M USD | −7.63M USD | −2.7M USD |
| Net income | −13.24M USD | −10.65M USD | −8.36M USD | −6.71M USD |
Company facts updated Aug 24, 2026.
CVKD news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 20, 2024 | 1:15 | — | — |
Effective Aug 20, 2024
1:15
CVKD peers
ETFs holding CVKD
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 66.89K
- Weight
- —
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 33.89K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 1.45K
- Weight
- 0.00%
- AUM
- 2.35B USD
- Expense ratio
- 0.15%
- Price / 1D
- $48.20+0.52%
Continue in GoAI
Research CVKDresearch.disclaimer